Quarterly report [Sections 13 or 15(d)]

Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details)

v3.25.2
Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - Reporting Segment [Member] - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Schedule of Reconciliation to the Consolidated Net Loss [Line Items]        
General and administrative $ 1,460,723 [1] $ 1,300,277 [1] $ 3,157,148 $ 3,197,996
Pre-clinical research 103,343 [1] 796,595 [1] 165,336 1,226,979
CMC 99,413 [1] 420,951 [1] 324,010 798,771
Clinical development 1,928,275 [1] 1,068,655 [1] 3,363,079 1,894,772
Depreciation and amortization 161,746 162,257 323,454 324,514
Share based compensation expense 57,645 160,952 156,203 507,429
Other segment items (246) [2] 35,347 [2] 1,848 35,347
Total operating and segment expenses 3,810,899 3,945,034 7,491,078 7,985,808
Reconciliation of net loss        
Change in fair value of warrant liabilities (8,436) (35,622) 68,431 (8,906)
Realized foreign currency translation loss from dissolution of subsidiaries (7,171)
Foreign currency gain/(loss) 29,290 29,290
Other income 19,464 19,464
Interest and dividends, net 54,424 114,407 101,669 267,625
Segment and consolidated net loss $ 3,716,157 $ 3,866,249 $ 7,279,395 $ 7,727,089
[1] includes personnel costs and excludes share-based compensation expense
[2] includes loss from sale of assets, and loss on asset write offs